HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FTC Section 13(b) Revamp Gains Traction With Senate ‘Fix’ In The Works

Executive Summary

There is strong support for a bipartisan fix to discourage marketplace fraud and anticompetitive practices and enable consumer redress under the FTC Act. But Congress is distracted and deeply divided with different ideas about how extensive the FTC’s authorities should be under Section 13(b) of the FTC Act.

You may also be interested in...



House Bill Restoring FTC Monetary Relief Tool Stretches ‘Look Back’ Authority From 3 To 10 Years

Limiting FTC authority to enforcement started after legislation passes rather than all pending complaints as House bill allows could be divisive. But consumer health marketers question number of years before a complaint is filed agency can allege a business used false and misleading advertising under legislation the House passed.

Congressional Split Looms Over Including Retroactive Reach In FTC Monetary Relief Authority

Lawmakers disagree whether legislation to amend an FTC regulation to grant the commission authority to pursue monetary remedies should be retroactive, which would impact approximately 75 pending federal court cases alleging violations.

US House Appropriators Seek Data On Fragrance Allergens In Cosmetics, ‘Balance’ In Sunscreen Regs

The House Appropriations Committee asks the US Food and Drug Administration to provide a report to Congress in two years on the resources it would need to develop a database for fragrance allergens used in cosmetics. The committee’s report accompanying FY2023 FDA funding legislation also touches on OTC sunscreen regulation, PFAS in cosmetics, skin-lightening ingredients, and more.

Topics

Latest News
UsernamePublicRestriction

Register

RS152558

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel